The presence of tumor markers, such as CEA, carbohydrate antigen 15-3, cytokeratin 19 fragments, and cancer antigen 125, in the pleural fluid has been suggested as a complementary method to select patients for further invasive procedures to establish the diagnosis of MPE15–18. This evidence concerns the gene CEACAM5 and neoplasm.